-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The emergence of pharmaceutical R&D and production outsourcing (CXO) is to solve the problem of insufficient R&D capacity and optimization of resource allocation among pharmaceutical companies
.
Early CRO for pharmaceutical companies to provide only limited drug analysis service, and now CRO services has gradually penetrated into all aspects of drug development, including preclinical / clinical CRO, CMO / CDMO / CTDMO, CSO and so on
.
In addition to the continuous increase in service content, the CRO industry market has continued to expand in recent years, and related companies have begun to accelerate their deployment in this field
.
Recently, Wise Medicine signed a strategic cooperation agreement with Suzhou Xiangcheng District, planning to build another production base of Wise Medicine—Suzhou base in Huangdai Biomedical R&D Community
.
According to the agreement, the two parties will focus on innovative drugs, and also have a pre-clinical CRO platform for chemical drugs/biological drugs.
And early toxicology, biopharmaceutical process development and production of pre-clinical CRO research and development systems such as production of clinical samples
.
According to the data, Shanghai Ruizhi was established in 2003, mainly engaged in pre-clinical CRO services, including pre-clinical full-process pharmaceutical R&D services and pharmaceutical production outsourcing business.
It also has the CRO and CMO service capabilities for chemical drugs/biological drugs, focusing on innovative drugs.
.
Regarding the signing of this project, the industry believes that it means that the territory of Ruizhi Pharmaceutical's innovative drugs will be expanded again, and the pre-clinical CRO production capacity will also be greatly increased
.
In fact, in addition to the establishment of a production base in Suzhou this time, it has also been deployed in Shanghai Zhangjiang, Fengxian, Nantong, Chengdu, San Francisco and other places
.
Analysis believes that the reason why Ruizhi Pharmaceutical is continuously expanding its production base is mainly to meet the huge market demand and achieve its own further development
.
It is understood that in recent years, as the development of new drugs has become more difficult, the success rate of global new drug R&D has decreased, prompting global pharmaceutical companies to increase R&D investment and increase the demand for diversified technologies
.
In order to effectively reduce R&D costs, improve R&D efficiency, and meet the demand for diversified new technologies, pharmaceutical companies are constantly increasing the proportion of outsourcing new drug R&D
.
According to statistics, the total market size of drug discovery and preclinical research in global pharmaceutical R&D contract outsourcing will increase to 33.
9 billion US dollars by 2024, with a compound annual growth rate of 9% from 2020 to 2024
.
In this context, the domestic CRO industry is also in a stage of rapid development, with a compound growth rate of more than 30% overall; a compound growth rate of net profit of more than 40%; net profit margin greater than 20%, and ROE maintained at around 18-20%
.
The industry believes that the current domestic CRO companies, relying on the advantages of engineer dividends and integrated platform services, will do a lot in the wave of global innovative drug industry chain transfer, and will usher in more benefits
.
It is worth mentioning that in the future, as the penetration rate of domestic innovative drug R&D outsourcing continues to increase, more and more companies will also deploy in this field to promote the further development of the domestic CRO industry
.
However, it should be noted that although thanks to the domestic encouragement policy to promote the wave of innovative drugs, the awareness of new drug patent protection continues to increase, the domestic drug preclinical research and development service market will grow at a faster rate than the global market
.
But at the same time, the competition among CRO companies will become increasingly fierce
.
Compared with small and medium-sized enterprises, CRO companies with scale advantages and core competitiveness are expected to be more competitive in the future
.
.
Early CRO for pharmaceutical companies to provide only limited drug analysis service, and now CRO services has gradually penetrated into all aspects of drug development, including preclinical / clinical CRO, CMO / CDMO / CTDMO, CSO and so on
.
In addition to the continuous increase in service content, the CRO industry market has continued to expand in recent years, and related companies have begun to accelerate their deployment in this field
.
Recently, Wise Medicine signed a strategic cooperation agreement with Suzhou Xiangcheng District, planning to build another production base of Wise Medicine—Suzhou base in Huangdai Biomedical R&D Community
.
According to the agreement, the two parties will focus on innovative drugs, and also have a pre-clinical CRO platform for chemical drugs/biological drugs.
And early toxicology, biopharmaceutical process development and production of pre-clinical CRO research and development systems such as production of clinical samples
.
According to the data, Shanghai Ruizhi was established in 2003, mainly engaged in pre-clinical CRO services, including pre-clinical full-process pharmaceutical R&D services and pharmaceutical production outsourcing business.
It also has the CRO and CMO service capabilities for chemical drugs/biological drugs, focusing on innovative drugs.
.
Regarding the signing of this project, the industry believes that it means that the territory of Ruizhi Pharmaceutical's innovative drugs will be expanded again, and the pre-clinical CRO production capacity will also be greatly increased
.
In fact, in addition to the establishment of a production base in Suzhou this time, it has also been deployed in Shanghai Zhangjiang, Fengxian, Nantong, Chengdu, San Francisco and other places
.
Analysis believes that the reason why Ruizhi Pharmaceutical is continuously expanding its production base is mainly to meet the huge market demand and achieve its own further development
.
It is understood that in recent years, as the development of new drugs has become more difficult, the success rate of global new drug R&D has decreased, prompting global pharmaceutical companies to increase R&D investment and increase the demand for diversified technologies
.
In order to effectively reduce R&D costs, improve R&D efficiency, and meet the demand for diversified new technologies, pharmaceutical companies are constantly increasing the proportion of outsourcing new drug R&D
.
According to statistics, the total market size of drug discovery and preclinical research in global pharmaceutical R&D contract outsourcing will increase to 33.
9 billion US dollars by 2024, with a compound annual growth rate of 9% from 2020 to 2024
.
In this context, the domestic CRO industry is also in a stage of rapid development, with a compound growth rate of more than 30% overall; a compound growth rate of net profit of more than 40%; net profit margin greater than 20%, and ROE maintained at around 18-20%
.
The industry believes that the current domestic CRO companies, relying on the advantages of engineer dividends and integrated platform services, will do a lot in the wave of global innovative drug industry chain transfer, and will usher in more benefits
.
It is worth mentioning that in the future, as the penetration rate of domestic innovative drug R&D outsourcing continues to increase, more and more companies will also deploy in this field to promote the further development of the domestic CRO industry
.
However, it should be noted that although thanks to the domestic encouragement policy to promote the wave of innovative drugs, the awareness of new drug patent protection continues to increase, the domestic drug preclinical research and development service market will grow at a faster rate than the global market
.
But at the same time, the competition among CRO companies will become increasingly fierce
.
Compared with small and medium-sized enterprises, CRO companies with scale advantages and core competitiveness are expected to be more competitive in the future
.
